An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer.

Trial Profile

An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2012

At a glance

  • Drugs Zoledronic acid (Primary) ; Antineoplastics
  • Indications Malignant pleural effusion; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ZAP
  • Most Recent Events

    • 19 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 08 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top